A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

Category Primary study
JournalEuropean Journal of Cancer
Year 2014
This article has no abstract
Epistemonikos ID: 7461e2d6daa014d92d885035e908b57bf68a030f
First added on: Feb 06, 2025